Improving treatment for bone metastatic prostate cancer using combination therapies
The Radium-223 Combination Therapy Space; Improving Response and Clarifying Toxicities
This study is looking at how combining Radium-223 with other treatments can make it work better for men with advanced prostate cancer that has spread to the bones, while also trying to reduce side effects, so we can find the best options for different patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10792472 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of Radium-223, a treatment for bone metastatic castrate resistant prostate cancer (bmCRPC), by exploring its combination with other therapies. The study aims to understand how these combinations can improve drug delivery to cancer sites while minimizing side effects. By conducting multiple investigations, the research seeks to clarify which combinations are most beneficial and for which patients, addressing a critical gap in current treatment knowledge. Patients will be monitored for both positive and negative outcomes to refine treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with bone metastatic castrate resistant prostate cancer.
Not a fit: Patients with early-stage prostate cancer or those not diagnosed with bone metastases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and better quality of life for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promising results with alpha particle therapies, but this specific combination approach is novel and aims to fill existing knowledge gaps.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Thorek, Daniel Lyndon Jaffe — Washington University
- Study coordinator: Thorek, Daniel Lyndon Jaffe
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.